File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Tandem bispecific antibody prevents pathogenic SHIVSF162P3CN infection and disease progression

TitleTandem bispecific antibody prevents pathogenic SHIVSF162P3CN infection and disease progression
Authors
KeywordsHIV-1
AIDS
bi-bNAb
BiIA-SG
SHIV
Issue Date2021
PublisherElsevier (Cell Press): OAJ. The Journal's web site is located at http://cell.com/cell-reports
Citation
Cell Reports, 2021, v. 36 n. 8, p. article no. 109611 How to Cite?
AbstractAlthough progress has been made on constructing potent bi-specific broadly neutralizing antibody (bi-bNAb), few bi-bNAbs have been evaluated against HIV-1/AIDS in non-human primates (NHPs). Here, we report the efficacy of a tandem bi-bNAb, namely BiIA-SG, in Chinese-origin rhesus macaques (CRM) against the CRM-adapted R5-tropic pathogenic SHIVSF162P3CN challenge. Pre-exposure BiIA-SG injection prevents productive viral infection in 6 of 6 CRMs with unmeasurable proviral load, T cell responses, and seroconversion. Single BiIA-SG injection, at day 1 or 3 post viral challenge, significantly reduces peak viremia, achieves undetectable setpoint viremia in 8 of 13 CRMs, and delays disease progression for years in treated CRMs. In contrast, 6 of 8 untreated CRMs develop simian AIDS within 2 years. BiIA-SG-induced long-term protection is associated with CD8+ T cells as determined by anti-CD8β antibody depletion experiments. Our findings provide a proof-of-concept that bi-bNAb treatment elicits T cell immunity in NHPs, which warrant the clinical development of BiIA-SG for HIV-1 prevention and immunotherapy.
Persistent Identifierhttp://hdl.handle.net/10722/310166
ISSN
2023 Impact Factor: 7.5
2023 SCImago Journal Rankings: 4.279
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorNIU, M-
dc.contributor.authorWong, YC-
dc.contributor.authorWANG, H-
dc.contributor.authorLi, X-
dc.contributor.authorChan, CY-
dc.contributor.authorZHANG, Q-
dc.contributor.authorLING, L-
dc.contributor.authorCHENG, L-
dc.contributor.authorWANG, R-
dc.contributor.authorDU, Y-
dc.contributor.authorYim, LY-
dc.contributor.authorJIN, X-
dc.contributor.authorZHANG, H-
dc.contributor.authorZHANG, L-
dc.contributor.authorChen, Z-
dc.date.accessioned2022-01-24T02:24:50Z-
dc.date.available2022-01-24T02:24:50Z-
dc.date.issued2021-
dc.identifier.citationCell Reports, 2021, v. 36 n. 8, p. article no. 109611-
dc.identifier.issn2211-1247-
dc.identifier.urihttp://hdl.handle.net/10722/310166-
dc.description.abstractAlthough progress has been made on constructing potent bi-specific broadly neutralizing antibody (bi-bNAb), few bi-bNAbs have been evaluated against HIV-1/AIDS in non-human primates (NHPs). Here, we report the efficacy of a tandem bi-bNAb, namely BiIA-SG, in Chinese-origin rhesus macaques (CRM) against the CRM-adapted R5-tropic pathogenic SHIVSF162P3CN challenge. Pre-exposure BiIA-SG injection prevents productive viral infection in 6 of 6 CRMs with unmeasurable proviral load, T cell responses, and seroconversion. Single BiIA-SG injection, at day 1 or 3 post viral challenge, significantly reduces peak viremia, achieves undetectable setpoint viremia in 8 of 13 CRMs, and delays disease progression for years in treated CRMs. In contrast, 6 of 8 untreated CRMs develop simian AIDS within 2 years. BiIA-SG-induced long-term protection is associated with CD8+ T cells as determined by anti-CD8β antibody depletion experiments. Our findings provide a proof-of-concept that bi-bNAb treatment elicits T cell immunity in NHPs, which warrant the clinical development of BiIA-SG for HIV-1 prevention and immunotherapy.-
dc.languageeng-
dc.publisherElsevier (Cell Press): OAJ. The Journal's web site is located at http://cell.com/cell-reports-
dc.relation.ispartofCell Reports-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectHIV-1-
dc.subjectAIDS-
dc.subjectbi-bNAb-
dc.subjectBiIA-SG-
dc.subjectSHIV-
dc.titleTandem bispecific antibody prevents pathogenic SHIVSF162P3CN infection and disease progression-
dc.typeArticle-
dc.identifier.emailYim, LY: ayim@hku.hk-
dc.identifier.emailChen, Z: zchenai@hku.hk-
dc.identifier.authorityChen, Z=rp00243-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1016/j.celrep.2021.109611-
dc.identifier.pmid34433029-
dc.identifier.scopuseid_2-s2.0-85113408227-
dc.identifier.hkuros331446-
dc.identifier.volume36-
dc.identifier.issue8-
dc.identifier.spagearticle no. 109611-
dc.identifier.epagearticle no. 109611-
dc.identifier.isiWOS:000688508300046-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats